LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.
Gong L, Sun H, Liu L, Sun X, Fang T, Yu Z, Sui W, Xu J, Wang T, Feng F, Lei L, Rui W, Liu Y, Zhao X, An G, Lin X, Qiu L, Hao M.
Gong L, et al. Among authors: sun x.
Haematologica. 2024 May 30. doi: 10.3324/haematol.2024.285099. Online ahead of print.
Haematologica. 2024.
PMID: 38813706